Curevac N.V. (CVAC)
$81.19
0.91 (1.11%)
CVAC Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
125,722
Day's Range
79.21 - 82.02
52-Week Range
36.15 - 85.68
Dividend & Yield
N/A (N/A)
CVAC Stock Predictions, Articles, and Curevac N.V. News
CVAC Stock: CureVac Pops on Plans for Phase 2 Vaccine Trials
CureVac just announced it was launching Phase 2 trials in Peru and Panama for its coronavirus vaccine. CVAC stock is rallying in response.
Germany Makes a $299 Million Bet on CureVac
CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?
CureVac Stock Is Just Another Part of a Bigger Story
With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.
No Need to Rush Into CureVac Stock After Massive IPO Pop
CVAC stock is one of many intriguing plays on a Covid-19 vaccine. But 300% above the IPO price, investors seemingly have better options.
Why Science and Economics Might Justify CureVac
Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?
Is CureVac a Buy on the Pullback? It Depends
Recent IPO and vaccine play CureVac stock could bounce back – but tread carefully. Much of the upside remains priced into shares.
Why CureVac Might Soar From Here
The coronavirus vaccine play is crowded and CureVac stock needs to win more deals to get noticed
Go Easy on CureVac Stock After Its Red-Hot Market Debut
CureVac stock has been hot since its IPO thanks to its coronavirus vaccine candidate. Here's why you should give CVAC a breather now.
CureVac Stock Has Been Hot Following Its Recent IPO
CureVac has extensive collaborations globally as well as a range of drug candidates. CureVac stock is a high-risk, high-return investment.
CureVac Stock Soars After Talks of Supplying Vaccines for the EU
CureVac stock soars after the company announced that it was in talks of supplying the vaccine to EU member states.
CureVac Is a Bet on a Safe and Effective Vaccine
CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over the next two years.
CureVac IPO: 13 Things for Potential CVAC Stock Investors to Know
The CureVac (CVAC) IPO is underway Friday and potential investors will want to keep an eye on the stock as it's seeing massive gains.
